The Addition of Target Therapy to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: A Review

被引：7

作者：

Benevento, Ilaria ^{[1
]}

De Felice, Francesca ^{[1
]}

Musio, Daniela ^{[1
]}

Tombolini, Vincenzo ^{[1
]}

机构：

[1] Sapienza Univ Rome, Policlin Umberto I, Dept Radiotherapy, Viale Regina Elena 326, IT-00161 Rome, Italy

来源：

CHEMOTHERAPY | 2017年 / 62卷 / 05期

关键词：

Rectal cancer; Locally advanced disease; Neoadjuvant treatment; Preoperative chemoradiotherapy; Target therapy; Epidermal growth factor receptor; Vascular endothelial growth factor receptor; Cetuximab; Bevacizumab; PHASE-II TRIAL; METASTATIC COLORECTAL-CANCER; PREOPERATIVE TREATMENT; RADIATION-THERAPY; DISEASE-CONTROL; CLINICAL-TRIAL; CAPECITABINE; RADIOTHERAPY; CETUXIMAB; BEVACIZUMAB;

D O I：

10.1159/000476056

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Currently, neoadjuvant fluoropyrimidine-based chemoradiotherapy (CRT) is standard practice in the management of locally advanced rectal cancer (LARC). In the last decade there has been a lively interest in the improvement of clinical outcomes by modifying this standard regimen by the addition of further agents. We review combinations of targeted therapies and conventional CRT currently under investigation in LARC patients. (C) 2017 S. Karger AG, Basel

引用

页码：314 / 322

页数：9

共 51 条

[1] Correlation of tumor regression grade (TRG), circumferential margin (CM), and epidermal growth factor receptor expression with disease-free survival (DFS) in locally advanced rectal cancer patients (LARC) treated with preoperative radiochemotherapy (preCh-RT). [J].

Arias, F. ;

Guerrero, D. ;

Gomez Dorronsoro, M. L. ;

Montes, M. ;

Vera, R. ;

Asin, G. ;

Monzon, F. ;

Balen, E. ;

Armendariz, P. ;

Vila, M. ;

Chicata, V. ;

Viudez, A. ;

Bandres, E. ;

Garcia-Foncillas, J. ;

DomAnguez, M. A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[2] Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms [J].

Bellati, Filippo ;

Napoletano, Chiara ;

Gasparri, Maria Luisa ;

Ruscito, Ilary ;

Marchetti, Claudia ;

Pignata, Sandro ;

Tomao, Federica ;

Panici, Pierluigi Benedetti ;

Nuti, Marianna .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 83 (01) :35-46

[3] NEOADJUVANT TREATMENT WITH SINGLE-AGENT CETUXIMAB FOLLOWED BY 5-FU, CETUXIMAB, AND PELVIC RADIOTHERAPY: A PHASE II STUDY IN LOCALLY ADVANCED RECTAL CANCER [J].

Bertolini, Federica ;

Chiara, Silvana ;

Bengala, Carmelo ;

Antognoni, Paolo ;

Dealis, Cristina ;

Zironi, Sandra ;

Malavasi, Norma ;

Scolaro, Tindaro ;

Depenni, Roberta ;

Jovic, Gordana ;

Sonaglio, Claudia ;

Rossi, Aldo ;

Luppi, Gabriele ;

Conte, Pier Franco .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (02) :466-472

[4] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].

Bonner, James A. ;

Harari, Paul M. ;

Giralt, Jordi ;

Cohen, Roger B. ;

Jones, Christopher U. ;

Sur, Ranjan K. ;

Raben, David ;

Baselga, Jose ;

Spencer, Sharon A. ;

Zhu, Junming ;

Youssoufian, Hagop ;

Rowinsky, Eric K. ;

Ang, K. Kian .

LANCET ONCOLOGY, 2010, 11 (01) :21-28

[5]

Cabebe EC, 2008, J CLIN ONCOL, V26, P15019

[6] PHASE II TRIAL OF NEOADJUVANT BEVACIZUMAB, CAPECITABINE, AND RADIOTHERAPY FOR LOCALLY ADVANCED RECTAL CANCER [J].

Crane, Christopher H. ;

Eng, Cathy ;

Feig, Barry W. ;

Das, Prajnan ;

Skibber, John M. ;

Chang, George J. ;

Wolff, Robert A. ;

Krishnan, Sunil ;

Hamilton, Stanley ;

Janjan, Nora A. ;

Maru, Dipen M. ;

Ellis, Lee M. ;

Rodriguez-Bigas, Miguel A. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (03) :824-830

[7] Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results [J].

Czito, BG ;

Willett, CG ;

Bendell, JC ;

Morse, MA ;

Tyler, DS ;

Fernando, NH ;

Mantyh, CR ;

Blobe, GC ;

Honeycutt, W ;

Yu, DH ;

Clary, BM ;

Pappas, TN ;

Ludwig, KA ;

Hurwitz, HI .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (04) :656-662

[8] Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results [J].

Czito, Brian G. ;

Bendell, Johanna C. ;

Willett, Christopher G. ;

Morse, Michael A. ;

Blobe, Gerard C. ;

Tyler, Douglas S. ;

Thomas, John ;

Ludwig, Kirk A. ;

Mantyh, Christopher R. ;

Ashton, Jill ;

Yu, Daohai ;

Hurwitz, Herbert I. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (02) :472-478

[9] Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience [J].

De Felice, Francesca ;

Musio, Daniela ;

Magnante, Anna Lisa ;

Bulzonetti, Nadia ;

Benevento, Ilaria ;

Caiazzo, Rossella ;

Tombolini, Vincenzo .

CLINICAL COLORECTAL CANCER, 2016, 15 (02) :E17-E22

[10] Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer [J].

Debucquoy, Annelies ;

Haustermans, Karin ;

Daemen, Anneleen ;

Aydin, Selda ;

Libbrecht, Louis ;

Gevaert, Olivier ;

De Moor, Bart ;

Tejpar, Sabine ;

McBride, William H. ;

Penninckx, Freddy ;

Scalliet, Pierre ;

Stroh, Christopher ;

Vlassak, Soetkin ;

Sempoux, Christine ;

Machiels, Jean-Pascal .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) :2751-2757

← 1 2 3 4 5 6 →